Baylor College of Medicine

A Study to Evaluate Oral TAK-071 in Parkinson's Disease Patients with Cognitive Impairment and Elevated Risks of Falls (H-47965)

Description

Content

A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson's Disease Patients with Cognitive Impairment and Elevated Risks of Falls. 

TAK-071 is an investigational drug that is being studied as a possible treatment for people with Parkinson's Disease who have a history of falls.  Falls are a common cause of injury in patients with Parkinson's Disease.  The cause of falls is due to several reasons and involves interactions between environmental, motor, and cognitive factors.  

You may be eligible for this study if:

  • you are up to 85 years of age
  • have been diagnosed with Parkinson's Disease
  • have cognitive impairment and a history of falling

Contact

Rory Mahabir

Phone 1: 832–496–4488

IRB: H-47965

Status:

Active

Created:

Back to topback-to-top